Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Change in Cash (2021 - 2026)

HeartSciences posted quarterly Change in Cash of $1.4 million for Q1 2026, up 199.34% year-on-year from $483046.6 in Q1 2025, and up 271.9% on a QoQ basis from -$841128.0 in Q4 2025.

HeartSciences (HSCS) has 6 years of Change in Cash data on file, last reported at $1.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Cash rose 199.34% year-over-year to $1.4 million; the trailing twelve-month figure through Jan 2026 stood at $800513.0 (up 117.87% YoY), and the FY2025 full-year result was -$4.7 million, down 213.56% from the prior year.
  • Change in Cash for Q1 2026 stood at $1.4 million, up from -$841128.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $7.0 million in Q1 2024 and bottomed at -$1.5 million in Q2 2025.
  • The 5-year median for Change in Cash is -$475510.0 (2023), against an average of $178038.6.
  • The widest annual swing landed in 2022, when Change in Cash plunged 428.37%; it then soared 709.28% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$1.2 million in 2022, then jumped by 60.26% to -$475510.0 in 2023, then surged by 39.51% to -$287658.0 in 2024, then plunged by 192.41% to -$841128.0 in 2025, then jumped by 271.9% to $1.4 million in 2026.
  • The last three Change in Cash figures came in at $1.4 million (Q1 2026), -$841128.0 (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 HeartSciences 4.56 Mn 1.16 Mn - 1.45 Mn

Historic Data

Download Data 🔒
DateValue
Jan 31, 2026 1.45 Mn
Oct 31, 2025 -841,128.00
Jul 31, 2025 1.69 Mn
Apr 30, 2025 -1.50 Mn
Jan 31, 2025 -1.46 Mn
Oct 31, 2024 -287,658.00
Jul 31, 2024 -1.47 Mn
Apr 30, 2024 -1.27 Mn
Jan 31, 2024 6.98 Mn
Oct 31, 2023 -475,510.00
Jul 31, 2023 -1.08 Mn
Apr 30, 2023 -270,485.00
Jan 31, 2023 -1.15 Mn
Oct 31, 2022 -1.20 Mn
Jul 31, 2022 3.35 Mn
Apr 30, 2022 -409,948.00
Jan 31, 2022 957,829.00
Oct 31, 2021 364,389.00
Jul 31, 2021 -717,491.00